Improving vitreoretinal surgery

Article

Treating the aetiology of recurrent vitreous haemorrhage improves patient outcomes

However, treatment options to deal with the factors associated with RVH after PPV do not address the aetiology of the problem or provide a cure. "Accordingly, there is no current consensus about the treatment of choice for these patients," added Drs Nadal and Carreras. "We believe that the results of our study could contribute to the improvement of two important factors in vitreoretinal surgery!"

"Our approach was based on direct treatment of the aetiology through eliminating the neovessels at the sclerotomy site and avoiding recurrence," said Drs Nadal and Carreras.

In eyes with sclerotomy site neovascularization, fibrovascular tissue can grow around the old incisions. This is as a result of a hypoxic response to peripheral retinal ischaemia and can favour movement of episcleral vessels through the sclerotomy site.

"Sclerotomies with incarcerated vitreous provide scaffold for ingrowing episcleral vessels eventually leading to new vessels being formed and recurrent vitreous haemorrhage occurring," they continued. "We proposed removal of any scaffold for neovascular growth by diathermy of sclerotomy site neovessels and ablation of existing retinal ischaemic tissue, which reduces hypoxic and/or angiogenic stimuli."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.